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Abstract
The HIV-1 envelope protein harbors several conserved epitopes that are recognized by broadly neutralizing antibodies. One
of these neutralizing sites, the MPER region of gp41, is targeted by one of the most potent and broadly neutralizing
monoclonal antibody, 2F5. Different vaccination strategies and a lot of efforts have been undertaken to induce MPER
neutralizing antibodies but little success has been achieved so far. We tried to consider the alternative anti-idiotypic
vaccination approach for induction of 2F5-like antibodies. The previously developed and characterized anti-idiotypic
antibody Ab2/3H6 was expressed as antibody fragment fusion protein with C-terminally attached immune-modulators and
used for immunization of rabbits to induce antibodies specific for HIV-1. Only those rabbits immunized with immunogens
fused with the immune-modulators developed HIV-1 specific antibodies. Anti-anti-idiotypic antibodies were affinity purified
using a two-step affinity purification protocol which revealed that only little amount of the total rabbit IgG fraction
contained HIV-1 specific antibodies. The characterization of the induced anti-anti-idiotypic antibodies showed specificity for
the linear epitope of 2F5 GGGELDKWASL and the HIV-1 envelope protein gp140. Despite specificity for the linear epitope
and the truncated HIV-1 envelope protein these antibodies were not able to exhibit virus neutralization activities. These
results suggest that Ab2/3H6 alone might not be suitable as a vaccine.
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Introduction
Currently 33 million people are living with human immunode-
ficiency virus type 1 (HIV-1) worldwide. In 2009 2.6 million
people became newly infected and 1.8 million people died in the
course of AIDS [1]. During the last decades several efforts to
induce HIV-1 defending neutralizing antibodies (Abs) have failed
[2–4] but also promising results were reported [5], [6]. One of the
most potent neutralizing HIV-1 Abs isolated so far is the
monoclonal Ab (mAb) 2F5 [7–11] which binds to the membrane
proximal external region (MPER) of the virus envelope glycopro-
tein gp41 [12,13]. The potency of such neutralizing Abs alone and
in combination was demonstrated by passive immunization and
viral challenge in non-human primate models [14–17]. Therefore
the specific induction of likewise broadly neutralizing Abs against
the MPER, 2F5-like Abs, is a major goal for Ab-based HIV-1
vaccine strategies. Despite a strong humoral response to gp41
during the course of HIV-1 infection is evident [18], approaches to
elicit cross-clade neutralizing Abs against the MPER region were
difficult to achieve [19–21].
An alternative method to induce neutralizing Abs is the anti-
idiotypic (Id) approach. This approach is based on the idiotype
network theory postulated by Jerne about the Ab (Ab1) - anti-Id
Ab (Ab2) – anti-anti-Id Ab (Ab3) cascade stimulation, whereby
specific anti-Id Abs can serve as an "internal image" of the target
antigen and can be used to induce Ab3s that can bind to the
cognate antigen [22]. Anti-Id Abs have been proposed as vaccines
for cancer immunotherapy and significant success has been
achieved using anti-Id vaccines mimicking tumor-associated
antigens in animal studies [23–26] as well as in clinical trails
[27]. The anti-Id Ab Ab2/3H6 was developed at the Department
of Biotechnology [28] and is directed against mAb 2F5. The
chimeric as well as humanized version of Ab2/3H6 significantly
inhibits the binding of mAb 2F5 to its synthetic epitope
ELDKWA in an equimolar ratio and also decreases the in vitro
neutralization potency of mAb 2F5 in a dose-related manner [29–
31]. Ab2/3H6 is therefore estimated to mimic the epitope of mAb
2F5 and would be of great therapeutic interest as an anti-Id HIV-
1 vaccine. To improve the potency of the anti-Id Ab we designed
fusion proteins consisting of Ab2/3H6 Ab fragments (Ab2/
3H6
Fab) and C-terminally attached polypeptides to induce T-cell
responses against the virus.
One molecule with a wide range of biological activities is the
immune stimulatory cytokine interleukin 15 (IL15). It is involved
in the activation and proliferation of CD8+ T-cells and natural
killer T-cells, the maintenance of CD8+ memory cells, and the
differentiation and maturation of B cells [32,33]. Previous studies
have shown that the incorporation of IL15 into vaccinia-based
smallpox vaccine [34] or tuberculosis vaccine [35] induces high
avidity, long lived antigen specific memory T-cells as well as
persistent antigen specific Ab responses.
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‘‘promiscuous’’ T-cell epitopes from tetanus toxin (TT), measles
virus, or E6 transforming protein [36,37]. It has been proposed
that T-cells provide ‘‘help’’ to B cells under genetic control which
can be provided by incorporation into an effective vaccine.
Previous studies showed that co-immunization of the consensus
cavealin-1 binding domain peptide with the T-cell epitope from
TT increased the production of HIV-1 neutralizing Abs in a
macaque prime/boost study [38].
Therefore we recombinantly expressed fusion proteins of Ab2/
3H6
Fabs with the IL15 and alternatively an epitope of TT,
respectively. In this study we immunized rabbits with the different
Ab2/3H6
Fabs and evaluated the humoral immune response as well
as the neutralization potency of the obtained Ab3s to those
generated with Ab2/3H6
Fab only.
Materials and Methods
Ethics Statement
Serological tests of rabbits were performed at the Institute of
Small Farm Animals, Animal Production Research Center, Nitra
(Slovakia) in accordance with Slovak and EU regulations
concerning animal experiments (Slovak national law 115/1995).
Study approval was issued based on the study protocol by ethics
committee of the Institute of Small Farm Animals, Animal
Production Research Centre Nitra under the approval ID SK P
28004.
Expression Vectors
The Ab2/3H6
Fab expression vectors containing the murine
variable regions of Ab2/3H6 (ABP04229, ABP04230) and the
human constant CH1 and Ckappa regions were described
previously [29]. The coding region of the heavy chain (HC) genes
of Ab2/3H6
Fab-IL15 and Ab2/3H6
Fab –TT were cloned into
pcDNA3 (Invitrogen) containing the CMV promoter and the
neomycin phospho-transferase gene (neo). pIRESdhfr [39] was
used as backbone for the coding region of the Ab2/3H6 light
chain (LC). The genes of Ab2/3H6
Fab-IL15 HC and Ab2/3H6
LC were synthesized by Geneart (Regensburg, Germany) includ-
ing the Gaussia luciferase signal peptide [40] for both, the HC and
LC. The sequence of the human IL15 (P40933) gene was obtained
from the UniProtKB/Swiss-Prot database. The TT epitope
(YSYFPSV) [41] was introduced by PCR amplification of Ab2/
3H6
Fab HC sequence with the sense primer 59- ac-
cctggtgaccgtgtcc-39 and antisense primer 59- aggagcggccgcctata-
cagatggaaaatatgaataggcagatcctcctccgcc-39 containing a NotI re-
striction site for exchange of the IL15 tag.
Expression of Ab2/3H6
Fab Variants in CHO Cells
Stable cell lines were generated by co-transfection of corre-
sponding HC and LC plasmids into CHO dhfr negative cells
(ATCC CRL-9096; [42]). Clones were selected with Geneticin
G418 (Fisher Scientific) and methotrexate (MTX) (Sigma) in
combination with limiting dilution subcloning. Collected super-
natants were concentrated by the Stirred cell 8200 with UF Discs
Ultracel RC 10 kD (Millipore) before purification.
Purification of Ab2/3H6
Fab Variants
Purification of all Ab2/3H6
Fab variants was performed on a
BioLogic Duo Flow chromatography system (Biorad). Concen-
trated cell culture supernatant was diluted 1:2 in buffer A (20 mM
Na2HPO4, pH 7.2) and filtered through a 0.22 mm syringe filter
(Millipore). The UNO Q 1.3 ml anion exchange (AIX) column
(Biorad) was equilibrated with 5 column volumes (cv) buffer A.
Five millilitre of the concentrated sample were loaded onto the
column using direct injection via the DuoFlow F40 pump at a flow
rate of 1 ml/min corresponding to a linear velocity of 155.9 cm/h.
The column was washed with buffer A until the optical density
returned to base line. Ab2/3H6
Fabs were eluted from the AIX
column using a 3 step gradient of 20, 40 and 100% of buffer B
(20 mM Na2HPO4, 1 M NaCl pH 7.2) in buffer A in 5 cv at a
flow rate of 1.0 ml/min (155.9 cm/h). Ten microlitres samples
from the eluted AIX chromatography fractions were analysed by
SDS-PAGE and NN-silver stain. Quantification of Ab2/3H6
Fab
was done by double sandwich enzyme-linked immunosorbent
assay (ELISA). Ab2/3H6
Fab containing fractions were further
purified on a Superdex 75 prep grade Tricorn 10/300 column
(GE) with PBS as mobile phase at a flow rate of 0.5 ml/min,
corresponding to a linear velocity of 38.2 cm/h.
Animals and Immunization
Ab2/3H6
Fab, -IL15, and -TT preparations were used for the
immunisation of New Zealand white rabbits. Six rabbits (groups of
two rabbits per preparation) were immunised subcutaneously and
intramuscularly with 0.1 mg of purified Ab2/3H6
Fab proteins
emulsified in complete Freund’s adjuvant and boosted two times
with the same Fab preparations in incomplete Freund’s adjuvant
at three-week intervals.
Purification of Antibody Fractions from Crude Sera
Purification of rabbit IgG. Purification of rabbit IgG from
crude sera was performed on an A ¨kta Purifier chromatography
system (GE) with the UNOsphere SUPrA Mini cartridge column
(Biorad). IgGs were eluted from the Protein A column using a step
gradient of 80% of buffer B (100 mM Glycin pH 3.5) in buffer A
(100 mM Glycin, 100 mM NaCl, pH 7.0). Quantification of
rabbit IgG was done by double sandwich ELISA.
Immunoaffinity purification of gp140/ELDKWA specific
Ab3s. HIV-1 specific Ab3s were purified from rabbit IgG
fractions using an affinity column coupled with recombinant
gp140 (HIV-1 cladeA, 92/UG/037), named UG37 [43] and the
synthetic mAb 2F5 epitope (GGGELDKWASL). The affinity
matrix was prepared with the AminoLink Plus Immobilization Kit
(Thermo Scientific) following the manufacturer’s instructions.
Briefly, a mixture of 1.5 mg UG37 combined with 0.5 mg
GGGELDKWASL (both Polymun Scientific, Inc) was coupled
to the beads using the pH 10 coupling procedure. Pooled rabbit
IgG fractions were diluted 1:2 with binding buffer and 2 ml
batches were incubated with the conjugated beads for 1h at RT.
The eluted fractions were pooled, concentrated using Amicon
Ultra-15 3k columns (Millipore) and named Ab3 pool.
Evaluation of Humoral Immune Response
ELISA. Rabbit IgG concentration and specificity for Ab2/
3H6
Fab and HIV-envelope were analysed by ELISA. The 96-well
microtiter plates (Nunc) were coated over night at 4uC with 1 mg/
mL of anti-rabbit IgG (Sigma), Ab2/3H6
Fab, UG37 or
GGGELDKWASL peptide, respectively. Plates were blocked
with PBS containing 3% BSA and 0.1% Tween 20 in PBS (RT,
1 h) and incubated with serial twofold dilutions of heat inactivated
serum samples or purified rabbit IgG (RT, 1 h). Afterwards plates
were incubated with peroxidase-conjugated anti-rabbit IgG
antibody (Sigma) and reactions were visualised with o-phenylene-
diamine and H2O2 (Merck). Cut-off values were estimated from
ELISA using the two-fold OD value of the negative control.
Affinity analysis. Bio-Layer Interferometry (BLI) was used
for determination of binding affinity of Ab3s and 2F5 single chain/
fragment crystallisable fusion protein (2F5scFc) at a starting
Anti-Idiotypic Antibody HIV-1 Vaccine
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with the Octet QK (forte ´Bio). Streptavidin (SA) biosensor tips were
loaded with 13 mg/mL of biotinylated UG37 or biotinylated
GGGELDKWASL peptide according to the manufacturer’s
instructions. The assay was performed at 30uC in PBS buffer
with 1000 rpm agitation. Association and dissociation curves
(5 min each) were recorded for the individual samples and data
were processed and analyzed using the Octet data analysis
software 6.4 (forte ´Bio).
Competition assay. BLI was used for competition experi-
ments as describes elsewhere [44]. Biotinylated GGGELDK-
WASL peptide or biotinylated UG37 was coupled onto SA
biosensor tips. Antigen coated tips were dipped into wells of
2F5scFc or the Ab3 pool (each at 400 nM, 5 min) until saturation,
and then moved into wells containing the ‘‘competing’’ Ab (Ab3s
or 2F5scFc; 400 nM, 5 min).
Neutralization assay. Pseudotyped virions were generated
in HEK293T (ATCC: CRL-11268) cells by co-transfection with
HIV-1 Env plasmid SF162 (NIHARRRP; contributed by
L. Stamatatos and C. Cheng-Mayer) and the HIV-1 Env-deleted
backbone plasmid pSG3DEnv (NIHARRRP; contributed by
J. Kappes and X. Wu), as previously described [45]. Virions were
added to the same volume of serially diluted mAbs (starting at
25 mg/mL) and incubated for 1 h at 37uC. Then, freshly
trypsinized TZM-bl reporter cells (NIHARRRP; contributed by
J. Kappes and X.Wu) (10,000 cells in 100 mL growth medium
supplemented with DEAE-dextran at a final concentration of
10 mg/mL) were added and the plates were incubated at 37uC.
After 48 h incubation, the medium was removed and 50 mL lysis
buffer (25 mM glycylglycin, 15 mM MgSO4, 4 mM EDTA, 1%
Triton X-100 in H2O, pH 7.8) was added. Finally, 50 mL Bright-
Glo reagent (Promega) was added and luminescence was measured
using a luminometer (Tecan). All experiments were performed at
least in duplicate. The IC50 was calculated with GraphPad Prism
5.04 (GraphPad Software, Inc.) using a four parameter fit.
Results
Expression and Purification of Ab2/3H6
Fab Fusion
Proteins
Ab2/3H6
Fab fusion proteins (Figure 1A) were expressed in
CHO cells by cotransfecting pAb2/3H6
Fab-IL15 or pAb2/
3H6
Fab-TT in combination with pAb2/3H6LC. The previously
developed recombinant cell line expressing Ab2/3H6
Fab [29] was
used for purification of Ab2/3H6
Fab. Culture supernatants
containing approximately two mg of each of the recombinant
Ab2/3H6
Fab variants were purified on a Q-Sepharose column
followed by a size-exclusion step. Purified proteins were quantified
by ELISA, and analyzed by SDS-PAGE and Western Blot
(Figure 1B).
Humoral Immune Response in Rabbits
New Zealand white rabbits were immunized with three different
Ab2/3H6
Fab variants in duplicates in a prime/boost regime. Ten
days after the final boost animals were bled to death and serum
was collected. Afterwards IgG was purified from rabbit sera to
avoid nonspecific binding of accompanied serum proteins. Pre-
immune sera and immune sera of all immunized animals as well as
sera of the two control rabbits were screened for total rabbit IgG
content ranging from 9 to 22 mg/ml per animal. Immunization
with the IL15 or TT fusion protein did not increase total IgG
levels significantly compared to immunization with Ab2/3H6
Fab
(data not shown). Samples from individual rabbits were coded
accordingly: Fab-1 and Fab-2 for Ab2/3H6
Fab immunized
animals; IL15-1 and IL15-2 for Ab2/3H6
Fab-IL15 immunized
Figure 1. Design and purification of Ab2/3H6
Fab variants. Three different Ab2/3H6
Fab preparations were developed for the immunization
study. Panel A. displays (a) the Fab-fragment HC of Ab2/3H6 named Ab2/3H6
Fab.( b) human IL15 fused to Ab2/3H6
Fab named Ab2/3H6
Fab-IL15 and
(c) a tetanus toxin epitope fused to Ab2/3H6
Fab named Ab2/3H6
Fab-TT. The chimeric mouse 3H6vL/hukappa LC (214 aa) is not shown. Panel B. shows
the non-reduced SDS-gel of purified Fabs; silver stain (SS) on the left side and the Western Blot (WB) on the right side developed using an anti-human
Fab specific antibody and visualized with NBT/BCIP. The lanes 1 represents Ab2/3H6
Fab-TT (49 kD); lane 2: Ab2/3H6
Fab-IL15 (61 kD); lane 3: Ab2/3H6
Fab
(47 kD) and M represents the marker. The double band is significant for glycosylated Ab2/3H6 [61].
doi:10.1371/journal.pone.0039063.g001
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Fab and UG37. Purified rabbit IgG fractions immunized with
different Fab preparations, the pre-immune IgG fractions and the IgG fractions of the control animals were tested in a binding ELISA. Diluted IgG
fractions from individually immunized rabbits binding to Ab2/3H6
Fab (A; upper panel) and associated pre-immune/control fractions (A; lower panel)
as well as diluted IgG fractions from individually immunized rabbits binding to UG37 (B; upper panel) and associated pre-immune/control fractions
(B; lower panel) are blotted against the OD-value. (Samples codes: Fab for Ab2/3H6
Fab, IL15 for Ab2/3H6
Fab-IL15 and TT for Ab2/3H6
Fab-TT immunized
rabbits).
doi:10.1371/journal.pone.0039063.g002
Table 1. Fisher’s Exact test.
Ab2/3H6
Fab binding immunized rabbits pre-immune sera and control animals Total
YES 60 6
NO 08 8
Total 68 1 4
UG37 binding
rabbits immunized with immune-
modulators
rabbits immunized without immune-
modulators Total
YES 31 4
NO 02 2
Total 33 6
Fisher’s Exact test two-tailed.
p=0.0003.
p.0.05 (highly statistically significant).Fisher’s Exact test two-tailed.p=0.4000.p.0.05 (not statistically significant).
doi:10.1371/journal.pone.0039063.t001
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Fab-TT immunized animals
and N-1 and N-2 for control rabbits.
Specificity against Ab2/3H6
Fab and HIV-1 epitopes. The
specificity of IgG fractions to the Ab2/3H6
Fab antigen was
estimated in an ELISA starting with a concentration of 10 mg/ml
rabbit IgG. Fab-1, Fab-2, IL15-1, IL15-2 and TT-1 samples show
a similar binding curve resulting in cut-off concentrations between
0.2 mg/ml and 0.5 mg/ml whereas the TT-2 sample (cut-off
1.4 mg/ml) shows weaker binding (Figure 2A; upper panel). Rabbit
IgG of purified pre-immune sera as well as control animals showed
no binding towards Ab2/3H6
Fab (Figure 2A; lower panel).
Additionally, the IgG fractions were tested on HIV-1 envelope
protein UG37 coated ELISA plates with a starting concentration
of 125 mg/ml rabbit IgG. The rabbit IgG samples IL15-1, IL15-2
and TT-2 showed significant specificity to UG37 as shown in
Figure 2B (upper panel) with cut-off concentrations of 21, 7 and
6 mg/ml. Fab-1, Fab-2 and TT-1 did not bind to UG37 despite
the immunized rabbits developed antibodies with high specificity
for the immunogen Ab2/3H6
Fab. One of the pre-immune samples
(from animal IL15-1) bound to UG37 (Figure 2B; lower panel).
This pre-immune fraction exhibits a 5-fold stronger binding to
UG37 than the corresponding immune-fraction. The reason for
this unexpected result is not clear.
The statistical significance between immunized and non-
immunized rabbits or rabbits immunized with the immune-
modulator fusion proteins and Ab2/3H6
Fab was analysed using
the Fisher’s Exact test (p,0.05).
The calculated p-value for the induction of anti-Ab2/3H6
Fab
Abs is 0.0003 (Table 1) indicating a strong significant correlation
between immunized and non-immunized animals. The p-value for
the induction of anti-UG37 Abs is 0.4000 (Table 1) indicating no
statistical significance using Ab2/3H6
Fab Abs with or without
immune-modulators.
Characterization of the immunoaffinity purified Ab3
pool. Pooled rabbit IgG samples IL15-2 and TT-2 were purified
with a second affinity purification step, using a UG37/
GGGELDKWASL coupled column. The results of the affinity
purification step are summarized in Table 2 and show that only
1.5% of the rabbit IgG fraction contained Ab3s. The collected
Ab3 pool was tested for specificity to UG37 and the linear epitope
GGGELDKWASL starting with 1 mg/ml rabbit IgG in ELISA.
UG37 and GGGELDKWASL specificity was estimated by cut-off
values (Figure 3) indicating approximately 10-fold stronger binding
of the Ab3 fraction to the linear epitope GGGELDKWASL than
to UG37. In comparison mAb 2F5 exhibits a seven-fold weaker
binding to UG37 than to GGGELDKWASL (Figure 3).
We confirmed the ELISA binding studies with affinity analysis
using BLI. GGGELDKWASL or UG37 coated sensor tips were
used for affinity measurements of the specific Ab3 pool. Sample
and 2F5scFc as positive control were measured in decreasing
concentrations (400, 200, 100 and 50 nM). Figure 4A
(GGGELDKWASL biosensor tips) and Figure 4B (UG37 biosen-
sor tips) display the association and dissociation curves, indicating
specific binding and dissociation of the induced Ab3s to both
GGGELDKWASL and UG37. The binding properties shown by
the kon,k off and KD values of 2F5scFc and the Ab3 pool to
GGGELDKWASL are comparable meaning similar affinity of
2F5scFc and Ab3 pool to the synthetic epitope while the affinity of
the Ab3 pool to UG37 is five-fold lower compared to 2F5scFc
(Table 3).
Competition assay. Competition tests were generated using
the BLI method to verify the specificity of the induced Ab3s to
GGGELDKWASL and UG37. The assay setup is shown in
Figure 5 (upper panel). GGGELDKWASL or UG37 saturated tips
were incubated with the Ab3 pool. For competition the sensor tips
were transferred to a solution of 2F5scFc or the Ab3s for self-
competition as control. The obtained competition curves indicate
that 2F5scFc is able to displace the Ab3 pool from both epitopes
(GGGELDKWASL and UG37) (Figure 5A). In a second assay
2F5scFc was allowed to bind to GGGELDKWASL or UG37 tips
until saturation. Afterwards the saturated sensor tips were
transferred to a solution of the Ab3 pool for competition or
2F5scFc for self-competition as control. The recorded competition
curves showed that the Ab3 fraction was not able to compete with
2F5scFc (Figure 5B).
Neutralization assay. To investigate the neutralization
potency of the purified gp140 specific Ab3 pool a TZM-bl Env-
pseudotyped virus assay against the HIV-1 SF162 Env clone was
performed. In this assay mAb 2F5 inhibits entry of the
pseudotyped virus with an IC50 of 130 ng/ml. The purified
Ab3s induced by immunization of rabbits with Ab2/3H6 shows no
neutralization activity (data not shown).
Discussion
The global HIV pandemic is still expanding and thus the
development of a preventive vaccine is of high priority. One
approach is to elicit broadly neutralizing Abs against the MPER
Table 2. Mass balance of Ab3 affinity purification.
total IgG [mg] Yield [% of rabbit IgG]
rabbit IgG 8.00 –
Flow through 5.54 69.2
Wash 2.29 28.7
Ab3 pool 0.12 1.5
The total rabbit IgG recovery after each run was approximately 99%.
doi:10.1371/journal.pone.0039063.t002
Figure 3. Cut-off values of the Ab3 pool binding to GGGELDK-
WASL and UG37. Affinity purified rabbit Ab3 pool was tested in a
binding ELISA for GGGELDKWASL and UG37 specificity. Cut-off values
were calculated for 2-fold the OD-value of the non immunized control
animal sera.
doi:10.1371/journal.pone.0039063.g003
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studies MPER-containing proteins [46,47] or MPER-containing
peptides [48–50] failed to elicit broadly neutralizing Abs,
presumably due to the poor immunogenicity of the MPER [21].
It was also suggested that the native gp41 exodomain is
structurally more complex than represented by the linear epitope
[51,52] and thus incorrect conformation of MPER-based peptide
immunogens result in suboptimal presentation of neutralizing
epitopes [53,54]. Additionally, a so far unidentified part of a
second epitope has been proposed [55] to interact with the long
CDR-H3 loop of mAb 2F5. This could be an alpha-helix C-
terminal of the core epitope DKW [56] or membrane compounds
from the infected cells [57–59]. Such a rather complex neutral-
izing epitope calls for an alternative vaccine approach and we
decided to continue with anti-Id antibodies. In previous studies
Ab2/3H6 showed promising results mimicking the gp41 epitope of
mAb 2F5. Gach et al. demonstrated that Ab2/3H6 is able to
inhibit the binding of mAb 2F5 to its synthetic epitope ELDKWA
and to induce Ab3s (2F5-like Abs) in a mouse immunization study
[29,30]. But due to the small amount of mouse sera obtained more
extensive characterizations could not be performed. Co-crystalli-
zation of Ab2/3H6 in complex with mAb 2F5 and comparison
with epitope/mAb 2F5 co-crystals revealed that Ab2/3H6 only
partly overlaps with the HIV-1 epitope on mAb 2F5 but does not
center on the core epitope binding site of mAb 2F5. Thus Ab2/
3H6 was classified as a gamma-class anti-Id Ab [60]. However,
since mAb 2F5 crystals were generated with a small peptide of the
MPER only, the exact binding mechanism of mAb 2F5 to HIV
remains elusive and the most critical paratope responsible for the
neutralization activity of mAb 2F5 might not be identified yet.
In this study we aimed to induce 2F5-like Abs using an anti-Id
network approach, instead of using MPER epitopes to elicit
neutralizing Abs. We constructed Fab fusion proteins of Ab2/3H6
containing the molecular adjuvant IL15 or a ‘‘promiscuous’’ T-cell
epitope of TT and administered them in a rabbit prime/boost
regime. Total rabbit IgG levels, Ab2/3H6
Fab and specificity for
HIV-1 epitopes were measured in an ELISA showing that the use
of IL15 and TT as immune stimulators do not significantly
influence total rabbit IgG levels (data not shown). However, after
protein A purification we were able to detect UG37 binding Ab3s
(Figure 2B) in three out of six animals. Interestingly these three
animals were immunized using fusion proteins of Ab2/3H6
Fab
with immune-modulators.
This observation could not be approved statistically (Table 1)
due to the small test group used and the fact that one animal
immunized with immune-modulator fusion protein did not show
binding to UG37. We strongly believe that by increasing the
number of animals tested the specificity and the advantage of
immune-modulators for induction of Ab3s might also be
confirmed statistically. In the next step we immunoaffinity purified
selected rabbit IgG samples to enrich the induced Ab3s using a
UG37/GGGELDKWASL coupled column with a rather low
recovery of 1.5% of the rabbit IgG fraction (Table 2). This
immunoaffinity enriched Ab3 pool shows significant binding to
GGGELDKWASL and also considerable interaction with UG37
(Figure 3 and 4). But affinities were lower compared to the
2F5scFc; approximately five-times lower for UG37 and slightly
lower for GGGELDKWASL (Table 3). Competition data revealed
that the purified Ab3 pool is not able to displace 2F5scFc for its
epitopes but on the other hand 2F5scFc replaces the Ab3 pool
from its binding to GGGELDKWASL and UG37 (Figure 5A and
5B). The lack of competition ability of the Ab3 pool is probably
based on the higher affinity of 2F5scFc for its epitopes. Since the
neutralization assays failed to indicate that neutralizing Abs were
generated in rabbits, we hypothesize a second epitope that is
responsible for the neutralization potency of mAb 2F5. Addition-
ally, the long H3 loop of mAb 2F5 indicates intensive somatic
mutagenesis and it is questionable if a seven week prime/boost
schedule in rabbits can reflect the maturation of the human
immune system.
To conclude on this study, Ab2/3H6 in combination with
immune-modulators like IL15 or TT was capable to induce anti-
anti-idiotypic Abs against the synthetic epitope of mAb 2F5 as well
as the HIV-1 envelope protein UG37. Despite the induced Ab3s
were not able to inhibit infection of TZM-bl cells in an Env-
pseudotyped neutralization assay Ab2/3H6 at least mimics part of
Figure 4. Affinity measurement of Ab3 pool to GGGELDKWASL and UG37. Affinity purified Ab3 pool and 2F5scFc were tested in a BLI assay
for binding affinity to GGGELDKWASL and UG37. Binding curves of mAb 2F5scFc (green) and Ab3 pool (blue) are displayed. Each antibody was
applied with a starting concentration of 400 nM and was further two-fold diluted in a dilution row. The data was fitted using the 1:1 model (curve-fit
not shown).
doi:10.1371/journal.pone.0039063.g004
Table 3. Summary of k-values for binding to HIV-1 epitopes.
mAb 2F5scFc Ab3 fraction
UG37 GGGELDKWASL UG37 GGGELDKWASL
kon
[1/Ms]
1.9610
05
(1.3)
1.2610
05
(0.4)
8.4610
04
(3.4)
1.9610
05 (0.5)
koff
[1/s]
9.5610
204
(3.2)
3.2610
204
(1.1)
2.3610
203
(1.3)
6.6610
204 (3.5)
KD
[nM]
7.1 (4.3) 2.7 (0.3) 33.3 (28.3) 3.6 (2.4)
standard deviation in brackets.
doi:10.1371/journal.pone.0039063.t003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39063the epitope. Affinity and competition data proved their specificity
but weaker binding of the induced Ab3s compared to mAb 2F5 is
evident.
After decades of intense research regarding the induction of
2F5-like Abs a potent immunogen that is able to induce broadly
neutralizing 2F5-like Abs is still missing. Deciphering the complete
and correct mechanism on how mAb 2F5 prevents gp41 to fuse
with the host cell membrane is the major task in developing HIV-1
vaccines able to induce broadly neutralizing anti-MPER Abs.
Unfortunately, the anti-Id approach using Ab2/3H6 does not lead
to the desired outcome.
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